Prophylactic nimodipine treatment improves hearing outcome after vestibular schwannoma surgery in men: a subgroup analysis of a randomized multicenter phase III trial

Christian Scheller1, Stefan Rampp1, Sandra Leisz1, Marcos Tatagiba2, Alireza Gharabaghi2, Kristofer F. Ramina2, Oliver Ganslandt3, Cordula Matthies4, Thomas Westermaier4, Gregor Antoniadis5, Maria T. Pedro5, Veit Rohde6, Kajetan von Eckardstein7, Konstanze Scheller8, Christian Strauss1

Received: 30 April 2020 / Revised: 29 July 2020 / Accepted: 11 August 2020 / Published online: 22 August 2020
© The Author(s) 2020

Abstract
A 2016 published randomized multicenter phase III trial of prophylactic nimodipine treatment in vestibular schwannoma surgery showed only a tendency for higher hearing preservation rates in the treatment group. Gender was not included in statistical analysis at that time. A retrospective analysis of the trial considering gender, preoperative hearing, and nimodipine treatment was performed. The treatment group received parenteral nimodipine from the day before surgery until the seventh postoperative day. The control group was not treated prophylactically. Cochlear nerve function was determined by pure-tone audiometry with speech discrimination preoperatively, during in-patient care, and 1 year after surgery and classified according to the Gardner-Robertson grading scale (GR). Logistic regression analysis showed a statistically significant effect for higher hearing preservation rates (pre- and postoperative GR 1–4) in 40 men comparing the treatment (n = 21) and the control (n = 19) groups (p = 0.028), but not in 54 women comparing 27 women in both groups (p = 0.077). The results were also statistically significant for preservation of postoperative hearing with pre- and postoperative GR 1–3 (p = 0.024). There were no differences in tumor sizes between the treatment and the control groups in men, whereas statistically significant larger tumors were observed in the female treatment group compared with the female control group. Prophylactic nimodipine is safe, and an effect for hearing preservation in 40 men with preoperative hearing ability of GR 1–4 was shown in this retrospective investigation. The imbalance in tumor size with larger tumors in females of the treatment group may falsely suggest a gender-related effect. Further investigations are recommended to clarify whether gender has impact on nimodipine’s efficacy.

Keywords Nimodipine · Men · Gender · Hearing preservation · Vestibular schwannoma surgery · Nerve protection

Christian Scheller and Stefan Rampp contributed equally to this work.

1 Department of Neurosurgery, Martin Luther University Halle-Wittenberg, Ernst-Grube-Str. 40, 06097 Halle (Salle), Germany
2 Department of Neurosurgery, University of Tübingen, Tübingen, Germany
3 Department of Neurosurgery, Stuttgart Hospital, Stuttgart, Germany
4 Department of Neurosurgery, University of Würzburg, Würzburg, Germany
5 Department of Neurosurgery, University of Ulm, Ulm, Germany
6 Department of Neurosurgery, University of Göttingen, Göttingen, Germany
7 Department of Neurosurgery, Westpfalz-Klinikum Kaiserslautern, Kaiserslautern, Germany
8 Department of Oral and Maxillofacial and Facial Plastic Surgery, Martin Luther University Halle-Wittenberg, Halle, Germany
Introduction

Scientific background and explanation of rationale

There are ongoing discussions about the best management of sporadic vestibular schwannomas (VS) particularly regarding hearing preservation. Unilateral hearing loss is associated with severe deterioration of quality of life with impaired speech recognition in noise, lack of directionality of sound, and daily fatigue [27]. In principle, possible options are wait and scan, radiotherapy, and microsurgery. Sughrue et al. analyzed 34 articles involving 982 patients with untreated sporadic VS. The overall hearing preservation rate was 54%, which was significantly associated with tumor growth rates [26]. Coughlin et al. reported poor long-term hearing preservation rates after radiotherapy with approximately 80% hearing preservation rate at 2 years posttreatment and approximately 23% after 10 years [3]. However, reported hearing preservation rates after microsurgery vary considerably between 2 and 93% [12]. Therefore, predictive factors for hearing preservation after microsurgical VS removal are important in particular for patient counseling and decision-making. Samii and Matthies reported the following predictive factors for hearing preservation after VS surgery in a series of 1000 cases: small to medium tumor size, good to moderate hearing, short duration of hypoacusis or vestibular disturbances, and male gender with chances of hearing preservation between 47 and 88% [21]. Nadol JB Jr. et al. also found in a series of 144 patients that male sex, smaller tumor size, and higher preoperative speech discrimination scores were significantly correlated with hearing outcome [16]. However, in other series with 792 and 104 patients, only tumor size and preoperative hearing but not male gender were predictive factors for preserved hearing in VS surgery [19, 20]. A retrospective analysis of 1269 patients with unilateral VS showed significant differences between males and females regarding tumor size and symptoms at the time of diagnosis with larger tumors and higher prevalence of hearing loss in men, whereas women more frequently suffered from dizziness [9].

Excluding the gender-specific characteristics, the previous studies suggest a neuroprotective beneficial effect of the prophylactic nimodipine administration in VS and maxillofacial surgeries [24, 25]. In addition, in vitro studies have shown that the pretreatment with nimodipine leads to reduced cell death of neuroblastoma, neuronal, astrocytic, and Schwann cells after mechanical, oxidative, osmotic, and heat-induced stress [10, 14].

Specific hypothesis

Considering these divergent findings, an additional, retrospective analysis of the 2016 published multicenter, randomized phase III trial investigating gender-related differences in hearing preservation rates after VS surgery with prophylactic nimodipine treatment was performed [24].

Material and methods

Regarding the detailed description of applied methods, the authors refer to the published paper on the phase III trial (e.g., sample size, randomization) [24]. The most important information is summarized as follows.

Trial design

The prospective, open-label, 2-arm, randomized, and multicenter study was conducted in compliance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines and approved by the German Competent Authority. The study protocol was approved by the Ethics Committee and all local review boards of the participating institutions. All patients granted informed consent prior to inclusion. No changes to methods were performed after the trial was started.

Participants

Adults from 18 years of age with an indication for VS surgery were included. Reasons for exclusion were contraindications against nimodipine, surgery for recurrent VS, pregnancy and lactation period, neurofibromatosis type 2, inoperability, preoperative facial nerve function grade VI according to the House-Brackmann (HB) grading scale [11], and participation in other clinical trials within the last 30 days.

Interventions

VS resections were performed by a retrosigmoid approach with neurophysiological monitoring (brainstem auditory evoked potentials, continuous facial nerve electromyography, and direct facial nerve stimulation). Nimodipine (1–2 mg/h; Nimotop®, Bayer, Leverkusen, Germany) was started the day before surgery and was continued until the seventh postoperative day. Individual dosage adjustments of nimodipine are described in the previous publication of the trial [24].

Outcomes, follow-ups, and blinding

Since there was a trend only for better hearing preservation rates (and not for facial nerve function) [24], only hearing function was considered for evaluation between males and females. Cochlear nerve function was documented preoperatively, during the in-patient stay, and 1 year after surgery. Hearing was determined by pure-tone audiometry with speech discrimination and
classified using the Gardner-Robertson (GR) scale [6]. Tumor size (according to the Koos grading system) and extent of resection were evaluated by a blinded neuroradiologist based on axial contrast-enhanced T1-weighted magnetic resonance imaging (MRI) performed preoperatively and 3 months after surgery for the multicenter trial [13].

**Statistical methods**

Effect-measure statistics were applied to evaluate risk differences. Results are expressed as probability to retain hearing. We used generalized linear models (GLM) with the binomial distribution and identity link. Due to the low number of patients with tumor sizes of Koos 1 and 4, the analysis was performed in a subgroup of patients with tumor sizes of Koos 2 and 3 (72 patients, see Table 2). A first model included treatment, gender, and tumor size as well as gender-size interactions. A second model additionally included gender-treatment interactions. Finally, for estimation of risk differences in male and female patients, respectively, separate models were calculated with terms for treatment and tumor size. GLM analysis was calculated using R [18].

In addition, hypothesis testing was conducted using chi-square and Student’s *t* test. Influence of different variables on outcome was analyzed using regression analysis (SPSS Statistics version 25, IBM Corp., Armonk, NY, USA).

**Results**

**Participant flow and numbers analyzed**

Fourteen of 112 enrolled patients were not suitable for further investigation (9 dropouts and 5 patients with preoperative GR 5), and 4 patients had to be excluded (two tumors in the cerebellopontine angle, two stage surgery, previously irradiated). The primary endpoint of the underlying multicenter study [24] was “facial nerve function 1 year after surgery.” Therefore, patients with preoperative hearing ability of Gardner-Robertson (GR) 5 (deaf) were included. For the present analysis of hearing outcome, patients with preoperative GR 5 had to be excluded. Subsequently, 94 patients (40 men and 54 women) were assigned to the treatment (men: *n* = 21; female: *n* = 27) or to the control group (male: *n* = 19; female: *n* = 27) (Fig. 1).

**Recruitment**

The authors refer to the published paper on the phase III trial [24].

**Baseline data**

The treatment and the control groups of both males and females were comparable in age, extent of resection, and preoperative cranial nerve function. There was no significant difference regarding tumor sizes between the treatment and the
control group in men. In contrast, tumors were significantly larger in the female treatment group as compared with control group \( (p = 0.028) \). As shown in Table 1, there were 12 women with Koos 2 tumors in the control and only 3 women with Koos 2 tumors in the treatment group. In contrast, larger tumors (Koos 3 and 4) were more frequently observed in the treatment group (14 versus 24 women) (Table 1).

### Outcomes and estimation

#### Hearing 1 year after surgery

Effect-measure statistics evaluated risk differences of hearing preservation 1 year after surgery. A first GLM with terms for treatment, gender, tumor size, and gender-tumor size interactions yielded a risk difference of \( RD = 0.19 \) (95% confidence interval: \(-0.03 \) to 0.39, \( p = 0.084 \)). Adding a gender-treatment interaction to this model resulted in interaction contrast for hearing preservation \( RD = 0.31 \) (\(-0.13 \) to 0.74, \( p = 0.17 \)). Risk differences of hearing preservation with and without treatment were \( RD = 0.36 \) (0.04 to 0.64, \( p = 0.016 \)) for male and \( RD = 0.05 \) (\(-0.27 \) to 0.34, \( p = 0.74 \)) for female patients.

Logistic regression analysis similarly showed an effect for higher hearing preservation rates (pre- and postoperative GR 1–4 and GR 1–3) in the male treatment \( (n = 21) \) compared with the male control \( (n = 19) \) group \( (p = 0.028 \) and \( p = 0.024 \), respectively), but not in females comparing 27 women in both groups \( (p = 0.077) \). Preoperative hearing of GR 1–2 was documented in 28 men (15 in the treatment and 13 in the control group). However, postoperative hearing ability of GR 1–2 was preserved in only five men (three patients in the treatment group). A robust statistical evaluation in men with preoperative GR 1–2 was therefore not possible.

Further subanalysis regarding tumor sizes showed statistically significant higher hearing preservation rates in males with Koos 2 tumors \( (p = 0.030, \text{Table 2}) \). In the male treatment group of Koos 2 tumors, hearing was preserved in 7 of 9 cases, whereas in the male control group of Koos 2 tumors, hearing was preserved in 2 of 8 cases. Regarding tumor sizes of Koos 3 and 4, there was no statistically significant difference. No reliable conclusions can be drawn for Koos 1 tumors \( (n = 1) \).

There were no differences observed regarding hearing preservation rates in females for both overall and all Koos subgroups \( (p = 0.709) \). However, all females with Koos 4 tumors of the control group became deaf, whereas in two of eight (25%), hearing was preserved in the female therapy group. Concerning Koos 2 tumors of females, no statistical evaluation is reasonable since 12 of 15 Koos 2 tumors were randomized to the control group (Table 2).

| Variable                              | Male patients | Female patients | Test     |
|---------------------------------------|---------------|----------------|----------|
|                                       | Control group | Treatment group | \( p \) value | Control group | Treatment group | \( p \) value | Test     |
| Mean age in years ± SD                | 46.2 (11.5)   | 48.5 (11.5)    | 0.903    | 49.9 (13.2)   | 48.6 (14.3)    | 0.587    | \( t \) test \( p = 0.028 \) |
| Koos grade (tumor size)               |               |                |          |               |                |          | Chi-square |
| 1                                     | 1             | 0              |          | 1             | 0              |          |          |
| 2                                     | 8             | 10             |          | 12            | 3              |          |          |
| 3                                     | 6             | 8              |          | 10            | 16             |          |          |
| 4                                     | 4             | 3              |          | 4             | 8              |          |          |
| GR class (preoperative hearing)       |               |                | 0.459    |               |                |          |          |
| 1                                     | 6             | 8              |          | 10            | 10             |          |          |
| 2                                     | 7             | 7              |          | 7             | 8              |          |          |
| 3                                     | 6             | 4              |          | 10            | 6              |          |          |
| 4                                     | 0             | 2              |          | 0             | 3              |          |          |
| 5                                     | 0             | 0              |          | 0             | 0              |          |          |
| HB grade (preoperative facial nerve function) |               |                | 0.168    |               |                |          | Chi-square |
| I                                     | 19            | 19             |          | 26            | 27             |          |          |
| II                                    | 0             | 2              |          | 1             | 0              |          |          |
| Extent of resection                  |               |                | 0.539    |               |                |          | Chi-square |
| Subtotal                             | 0             | 1              |          | 4             | 2              |          |          |
| 2–10 mm                              | 1             | 2              |          | 2             | 2              |          |          |
| Complete                             | 18            | 18             |          | 21            | 23             |          |          |

Table 1 Baseline data

In the female treatment group tumor sizes were significant larger compared to the female control group.
Facial nerve function 1 year after surgery

The GLM with terms for treatment, gender, tumor size, and gender-tumor size interactions yielded a risk difference of $RD = 0.02$ (95% confidence interval: $-0.16$ to $0.20$, $p = 0.81$).

Logistic regression analysis showed no gender-related effect and no interaction between nimodipine and gender regarding preservation of facial nerve function. Facial nerve function 1 year after surgery was HB I in 74% of the males and in 69% of the females ($p = 0.29$, chi-square test), HB II in 10% of the males and in 15% of the females, HB III in 12% of the males and in 14% of the females, HB IV in 2% of the males and in 1% of the females, and HB V in 2% of the males and in 1% of the females.

Adverse effects of treatment (harms)

As already described in previous studies [23, 24], nimodipine was well tolerated, and no drug-induced mortality or serious adverse events were observed. Dose-dependent hypotension resulting in dose reduction or discontinuing of nimodipine was the only relevant side effect [24].

Discussion

Limitations

Data from a prospective and randomized multicenter trial were evaluated in a retrospective way, which may result in some selection bias and in a possible overestimation of statistical results. Since tumor size was not a randomization factor in the original study [24], the imbalance regarding tumor sizes between the control and the treatment groups in women is the most relevant limitation for the evaluation of a gender-related effect. However, risk difference and logistic regression analysis showed a treatment effect for higher hearing preservation rates in men, although the confidence intervals for risk differences were rather broad. Considering that tumor size is one of the most reliable predictive factors for hearing preservation [22], it is surprising that there were no differences observed regarding hearing preservation rates in females between the control and the treatment group. This finding may be caused by a neuroprotective nimodipine effect, which however might be obfuscated by an imbalance of tumor sizes and the broad risk difference confidence intervals. In addition, the gender-treatment interaction contrast failed to show a clear gender difference. Therefore, it is possible that nimodipine preserves hearing function in both men and females. An evaluation bias is very unlikely since hearing ability was determined by pure-tone audiometries with speech discrimination and hearing abilities were classified by blinded expert reviewers. However, not only an administered neuroprotective agent but also several additional factors have impact on the hearing ability after VS surgery.

Generalisability

Gender- and nimodipine-related effects in vestibular schwannoma surgery

A professional literature research was performed. The following key words were used: nimodipine, gender, men, women, calcium channel blocker, subarachnoid hemorrhage, pharmacokinetics, sex-related differences, stroke, vestibular schwannoma, vasoactive, and neuroprotection.

Gelmers et al. reported a potential beneficial effect of early nimodipine treatment in acute ischemic strokes, which was limited to men [7].

A gender-related effect has also been discussed in presentation of VS, outcome after VS surgery, and regarding the efficacy of nimodipine treatment.

Samii et al. evaluated 1000 VS surgeries regarding factors influencing the chance of hearing preservation [22]. Advantageous factors were male gender, small to medium tumor sizes, good to moderate hearing, and short duration of hypoacusis or vestibular disturbances. Cadaveric studies showed that the mean lateral angle of the internal acoustic canal is greater in females (first line: medial petrous bone wall; second line: porus to fundus) [8, 15], which may influence the

### Table 2

| Tumor size (Koos) | Male patients ($n = 40$) | $p$ value (chi-square test) | Female patients ($n = 54$) |
|------------------|-------------------------|-----------------------------|-----------------------------|
|                  | Control group ($n = 19$) | Treatment group ($n = 21$)  | Control group ($n = 27$)    | Treatment group ($n = 27$) |
| 1                | 1/1                     | 0/0                         | 1/1                         | 0/0                         |
| 2                | 2/8                     | 7/9                         | 8/12                        | 2/3                         |
| 3                | 1/6                     | 3/8                         | 3/10                        | 6/16                        |
| 4                | 0/4                     | 1/4                         | 0/4                         | 1/8                         |

### Footnotes

[22]: Gelmers et al. reported a potential beneficial effect of early nimodipine treatment in acute ischemic strokes, which was limited to men [7].
angle of dissection between nerves and tumor and therefore outcome. Nevertheless, Al-Shudifat et al. reported in a retrospective series of 395 patients that female gender and patients over 50 years with larger tumor have a higher risk for reduced work capacity after VS surgery [1]. However, it remained unclear, if there is a correlation between hearing preservation rates and reduced work capacity in women.

Regarding nimodipine’s efficacy, sex-related differences of cytochrome P450 (CYP) 3A4 have been reported. CYP3A4 is responsible for the metabolism of nimodipine [4]. Considering women have higher CYP3A4 content in the liver [2], it may be possible that nimodipine is metabolized faster in women resulting in lower drug levels and reduced efficacy. Accordingly, Futuro-Neto et al. showed that female albino mice needed higher doses of nimodipine for neuroleptic-induced catalepsy than males [5].

Without considering tumor size and drug metabolism, the molecular mechanisms of this putative gender effect are unclear. In vitro, the antiapoptotic effect of nimodipine pretreatment is associated with the activation of AKT and CREB by phosphorylation [14]. Pan et al. showed recently in a rat model that the sex-dependent effects of the G protein-coupled estrogen receptor (GPER) activation, which plays a role in neuroprotection, depend on AKT activation [17]. In summary, it could be possible that the estrogen status or ER activation has an influence on the gender-specific nimodipine mode of action. Therefore, the influence of gender and hormone status on the nimodipine neuroprotective effect should be investigated further to shed light on sex differences in nimodipine treatment efficiency and enable a personalized neuroprotective therapy.

Interpretation

Cochlear nerve function 1 year after surgery

Nimodipine’s efficacy was predominantly observed in men with larger differences in patients with Koos 2 tumors. This might be interpreted as a gender-related nimodipine effect; however, statistical analysis did not reveal significant differences. The lack of a treatment effect in women could thus be mainly due to the imbalance of tumor sizes. Since hearing preservation rates are strongly influenced by tumor sizes, nimodipine is obviously more useful in tumor sizes with higher chances for postoperative hearing. This finding was limited to postoperative hearing classes GR 1–4 and GR 1–3, but not to GR 1–2. Due to the small sample size, further studies are needed to clarify if postoperative useful hearing (GR 1-2) also benefits from nimodipine treatment. For Koos 2 tumors in women, a robust statistical evaluation was not possible due to strongly unbalanced distribution with only 3 women in the treatment group.

Facial nerve function 1 year after surgery

A benefit from nimodipine for facial nerve outcome was not observed. Considering that in both the female and the male groups’ facial nerve function was excellent or good (HB 1–2) 1 year after surgery in 84%, a potential effect of nimodipine may not be detectable. In contrast to the cochlear nerve, the facial nerve has the potential for regeneration, which may influence the analysis of nimodipine’s efficacy.

Conclusions

In the presented retrospective analysis, prophylactic nimodipine was safe and preserved hearing predominantly in men with Koos 2 tumors but also in the male overall group. Whether the perioperative administration of nimodipine has also beneficial effects in women has to be clarified by further investigations. A possible gender effect should be investigated in further studies.

Acknowledgments

We thank Monika Göttlich, Jenny Hampel, Melanie Querfurt, Cornelia Seifert, and Christin Zöller, study nurses, for administrative contributions and assistance in performing this study.

Authors’ contributions

Conceptualization, C.S. and S.R.; methodology, C.S. and S.R.; software, S.R.; validation, C.S. and S.R.; formal analysis, C.S. and S.R.; investigation, all authors; resources, all authors; data curation, all authors; writing (original draft preparation), C.S., S.R., and S.L.; writing (review and editing), C.S. and S.L.; visualization, C.S. and S.R.; supervision, C.S.; project administration, C.S.; funding acquisition, C.S.

Funding information

Open Access funding provided by Projekt DEAL. The study is supported by the German Federal Ministry of Education and Research (BMBF 1315883); the Wilhelm-Roux-Program (FKZ 19/07, FKZ 23/26) of the University Halle-Wittenberg, Germany; Bayer Health Care, Germany; and the Acoustic Neuroma brain tumour and Interest Group, Switzerland.

Compliance with ethical standards

Conflicts of Interest

The authors declare that they have no conflict of interest.

Ethical approval

The study protocol was approved by the Ethics Committee and all local review boards of the participating institutions (EudraCT number: 2009-012088-32, protocol-number: KKSH-66).

Informed consent

All patients granted informed consent prior to inclusion. No changes to methods were performed after the trial was started.

Disclaimer

The sponsors had no role in the design, execution, interpretation, or writing of the study.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Al-Shudufat AR, Kahlon B, Högland P, Soliman AY, Lindskog K, Sjesjo P (2014) Age, gender and tumour size predict work capacity after surgical treatment of vestibular schwannomas. J Neurol Neurosurg Psychiatry 85:106–111. https://doi.org/10.1136/jnnp-2013-305168

2. Chen ML (2005) Confounding factors for sex differences in pharmacokinetics and pharmacodynamics: focus on dosing regimen, dosage form, and formulation. Clin Pharmacol Ther 78:322–329. https://doi.org/10.1016/j.clpt.2005.06.012

3. Coughlin AR, Hunt AA, Gubbels SP (2019) Is hearing preserved following radiotherapy for vestibular schwannoma? Laryngoscope 129:775–776. https://doi.org/10.1002/lary.27421

4. Cummins CL, Wu CY, Benet LZ (2002) Sex-related differences in dosing form, and formulation. Clin Pharmacol Ther 78(3):322–329. https://doi.org/10.1016/S0003-4975(02)00102-X

5. Futuro-Neto HA, Costa PG, Amorim SC, Saraiva FP, Ribeiro CA, Pires JG (1999) Evidence of sex related differences in the effects of calcium channel blockers on neuroleptic-induced catalepsy in mice. Prog Neuro-Psychopharmacol Biol Psychiatry 23:301–316. https://doi.org/10.1016/S0278-5846(98)00102-X

6. Gardner G, Robertson JH (1988) Hearing preservation in unilateral acoustic neuroma surgery. Ann Otol Rhinol Laryngol 97:55–66. https://doi.org/10.1177/000348988809700110

7. Gelmers HJ, Gorter K, de Weerdt CJ, Wierzer HJ (1988) A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med 318:203–207. https://doi.org/10.1056/NEJM198802183180404

8. Graw M, Wahl J, Ahlbrecht M (2005) Course of the meatus acusticus internus as criterion for sex differentiation. Forensic Sci Int 147:113–117. https://doi.org/10.1016/j.forsciint.2004.08.006

9. Harun A, Agrawal Y, Tan M, Niparko JK, Francis HW (2012) Sex and age associations with vestibular schwannoma size and presenting symptoms. Otol Neurotol 33:1604–1610. https://doi.org/10.1097/MAO.0b013e31826da9e

10. Herzfeld E, Strauss C, Simmermacher S, Bork K, Horstkorte R, Dehghani F, Scheller C (2014) Investigation of the neuroprotective impact of nimodipine on Neuron2a cells by means of a surgery-like stress model. Int J Mol Sci 15:18453–18465. https://doi.org/10.3390/ijms151018453

11. House JW, Brackmann DE (1985) Facial nerve grading system. Otolaryngol Head Neck Surg 93:146–147. https://doi.org/10.1177/019459988509300202

12. Kari E, Friedman RA (2012) Hearing preservation: microsurgery. Curr Opin Otolaryngol Head Neck Surg 20:358–366. https://doi.org/10.1097/MOO.0b013e3283597673

13. Koos WT (1988) Criteria for preservation of vestibulocochlear nerve function during microsurgical removal of acoustic neumomas. Acta Neurochir 92:55–66. https://doi.org/10.1007/bf01401974

14. Leisz S, Simmermacher S, Prell J, Strauss C, Scheller C (2019) Nimodipine-dependent protection of schwann cells, astrocytes and neuronal cells from osmotic, oxidative and heat stress is associated with the activation of AKT and CREB. Int J Mol Sci 20. https://doi.org/10.3390/ijms20184578

15. Matthies C, Samii M (1997) Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. Neurosurgery 40:1–9; discussion 9-10. https://doi.org/10.1097/00006123-199701000-00001

16. Nadol JB, Chong CM, Ojemann RG, McKenna MJ, Martuza RL, Montgomery WW, Levine RA, Ronner SF, Glynn RJ (1992) Preservation of hearing and facial nerve function in resection of acoustic neuroma. Laryngoscope 102:1153–1158. https://doi.org/10.1288/0005537-199210000-00010

17. Pan MX, Li J, Ma C, Fu K, Li QZ, Wang ZF (2020) Sex-dependent effects of GPER activation on neuroinflammation in a rat model of traumatic brain injury. Brain Behav Immun. https://doi.org/10.1016/j.bbi.2020.04.005

18. R Core Team (2019) R: a language and environment for statistical computing.

19. Robinette MS, Bauch CD, Olsen WO, Hamer SG, Beatty CW (1997) Nonsurgical factors predictive of postoperative hearing for patients with vestibular schwannoma. Am J Otolaryngol 18:738–745

20. Rohit, Piccirillo E, Ja in Y, Augurio A, Sanna M (2006) Hearing and facial nerve function during microsurgical removal of acoustic neuroma surgery. Ann Otol Rhinol Laryngol 97:55–66. https://doi.org/10.1177/019459988509300202

21. Samii M, Gerganov V (2013) Surgery of cerebellopontine lesions. Springer, Berlin Heidelberg. https://doi.org/10.1007/978-3-642-35422-9

22. Samii M, Matthies C (1997) Management of 1000 vestibular schwannomas (acoustic neuromas): hearing function in 1000 tumor resections. Neurosurgery 40:248–260; discussion 260-242. https://doi.org/10.1093/0006123-199701000-00005

23. Scheller C, Richter HP, Engelhardt M, Köening R, Antoniadis G (2007) The influence of prophylactic vasoactive treatment on cochlear and facial nerve functions after vestibular schwannoma surgery: a prospective and open-label randomized pilot study. Neurosurgery 61:92–97; discussion 97-98. https://doi.org/10.1227/01 neu.00000279728.98273.51

24. Scheller C, Wienke A, Tatagiba M, Gharabaghi A, Ramina KF, Ganslandt O, Bischoff B, Zenz J, Engelhorn T, Matthies C, Westermaier T, Antoniadis G, Pedro MT, Rohde V, von Eckardstein K, Kretschmer T, Kornhuber M, Steighardt J, Richter M, Barker FG, Strauss C (2016) Prophylactic nimodipine treatment for cochlear and facial nerve preservation after vestibular schwannoma surgery: a randomized multicenter phase III trial. J Neurosurg 124:657–664. https://doi.org/10.3171/2015.1.JNS142001

25. Scheller K, Scheller C (2014) Nimodipine for peripheral nerve recovery after maxillofacial and vestibular schwannoma surgery. Muscle Nerve 50:1026–1027. https://doi.org/10.1002/mus.24462

26. Sughrue ME, Yang I, Aranda D, Lobo K, Pitts LH, Cheung SW, Parsa AT (2010) The natural history of untreated sporadic vestibular schwannomas: a comprehensive review of hearing outcomes. J Neurosurg 112:163–167. https://doi.org/10.3171/2009.4.JNS08895

27. Zanoletti E, Mazzoni A, d’Avella D (2019) Hearing preservation in small acoustic neuroma: observation or active therapy? Literature review and institutional experience. Acta Neurochir 161:79–83. https://doi.org/10.1007/s00701-018-3739-x

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.